2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Nanomedicine to Overcome Current Parkinson's Treatment Liabilities: A Systematic Review.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Nanoparticles might be produced and manipulated to present a large spectrum of properties. The physicochemical features of the engineered nanomaterials confer to them different features, including the ability to cross the blood-brain barrier. The main objective of this review is to present the state-of-art research in nano manipulation concerning Parkinson's disease (PD). In the past few years, the association of drugs with nanoparticles solidly improved treatment outcomes. We systematically reviewed 28 studies, describing their potential contributions regarding the role of nanomedicine to increase the efficacy of known pharmacological strategies for PD treatment. Data from animal models resulted in the (i) improvement of pharmacological properties, (ii) more stable drug concentrations, (iii) longer half-live and (iv) attenuation of pharmacological adverse effects. As this approach is recent, with many of the described works being published less than 5 years ago, the expectancy is that this knowledge gives support to an improvement in the current clinical methods to the management of PD and other neurodegenerative diseases.

          Related collections

          Author and article information

          Journal
          Neurotox Res
          Neurotoxicity research
          Springer Science and Business Media LLC
          1476-3524
          1029-8428
          November 2016
          : 30
          : 4
          Affiliations
          [1 ] Department of Medicine, University Center of Maringá (UniCesumar), Maringa, Paraná, Brazil.
          [2 ] Department of Health Promotion, University Center of Maringá (UniCesumar), Cesumar Institute of Science Technology and Innovation (ICETI), Maringa, Paraná, Brazil. marcelo.bernuci@unicesumar.edu.br.
          [3 ] Department of Morphology Physiology and Basic Pathology, Dental School of Ribeirão Preto, University of São Paulo, Ribeirao Preto, São Paulo, Brazil.
          [4 ] Department of Neurosciences and Behavioral Sciences Ribeirao Preto Medical School, University of São Paulo, Ribeirao Preto, São Paulo, Brazil.
          [5 ] Department of Morphology Physiology and Basic Pathology, Dental School of Ribeirão Preto, University of São Paulo, Ribeirao Preto, São Paulo, Brazil. carol_issy@hotmail.com.
          Article
          10.1007/s12640-016-9663-z
          10.1007/s12640-016-9663-z
          27581037
          e268aa88-03b8-4bea-9c6d-6de26e89fe70
          History

          Nanomedicine,Nanoparticles,Nanotechnology,Parkinson’s disease

          Comments

          Comment on this article